- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar - Video
|
Overview
In this video, Dr. Naresh Kumar, Consultant Diabetologist from Tamil Nadu, presents a real-world case of a 24-year-old male student with fatigue and polyuria, diagnosed with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) risk.
The patient was initiated on a triple fixed-dose combination (FDC) of vildagliptin, dapagliflozin, and metformin, leading to rapid and sustained clinical improvements. Within just 4 weeks, fasting and postprandial blood glucose levels were effectively controlled. Over 6 months, HbA1c dropped significantly from 9.3% to 6.5%, reflecting excellent glycemic management. Notably, homocysteine levels normalized, reducing cardiovascular risk, while the patient reported marked improvement in energy levels, overall well-being, and quality of life.
This case underscores the value of early initiation of vildagliptin–dapagliflozin–metformin FDC in young patients with uncontrolled T2DM and elevated CV risk, highlighting its efficacy, safety, and potential to improve both metabolic and cardiovascular outcomes.
Speakers
Dr Naresh Kumar MBBS. He is consultant diabetologist currently practising in Vasuki Clinic, Coimbatore, Tamil Nadu.